Nyxoah S.A. (NYXH)
$9.6932
-0.31 (-3.07%)
Rating:
Recommendation:
-
| Symbol | NYXH |
|---|---|
| Price | $9.6932 |
| Beta | 0.000 |
| Volume Avg. | 0.01M |
| Market Cap | 257.316M |
| Shares () | - |
| 52 Week Range | 7.46-34.2 |
| 1y Target Est | - |
| DCF Unlevered | NYXH DCF -> | |
|---|---|---|
| DCF Levered | NYXH LDCF -> | |
| ROE | -21.25% | Sell |
| ROA | -14.56% | Sell |
| Operating Margin | - | |
| Debt / Equity | 20.71% | Neutral |
| P/E | - | |
| P/B | 1.54 | Strong Buy |
Latest NYXH news
About
Download (Excel)Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.